The effect of COVID-19 on patients with chronic spontaneous urticaria treated with omalizumab and antihistamines: A cross-sectional, comparative study.

Ecem BostanFethi ZaidAysen KaradumanSibel DoganDuygu GulserenBasak Yalici-ArmaganNeslihan AkdoganSibel Ersoy-EvansGonca Elcin

Published in: Journal of cosmetic dermatology (2021)

No statistically significant relationship was found between COVID-19 RT-PCR positivity and the type of treatment administered for chronic urticaria when the patients are divided into omalizumab ± oral antihistamines and only oral antihistamines treatment groups (p = 0.150). Omalizumab seems to be safe in the era of COVID-19.

Keyphrases

coronavirus disease
sars cov
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
prognostic factors
combination therapy
peritoneal dialysis
respiratory syndrome coronavirus
patient reported outcomes
replacement therapy